Filtered By:
Drug: Metformin
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 446 results found since Jan 2013.
Metformin enhances neural precursor cells migration and functional recovery after ischemic stroke in mice
Exp Brain Res. 2023 Jan 8. doi: 10.1007/s00221-023-06547-3. Online ahead of print.ABSTRACTResident neural precursor cells (NPCs) activation is a promising therapeutic strategy for brain repair. This strategy involves stimulating multiple stages of NPCs development, including proliferation, self-renewal, migration, and differentiation. Metformin, an FDA-approved diabetes drug, has been shown to promote the proliferation and differentiation of NPCs. However, it is still unclear whether metformin promotes the migration of NPCs. EVOS living cell imaging system was used for observing the migration for primary NPCs dynamically i...
Source: Cell Research - January 7, 2023 Category: Cytology Authors: Liang Zhang Jing Zhang Xiaoming Zhu Wei Jiao Yang Yang Youping Wu Likun Yang Yuhai Wang Source Type: research
Why Are Cardiologists Not Prescribing the New Diabetes Medications?
Randomized clinical trials and guidelines from multiple societies have established significant cardiovascular (CV) outcome benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D). Among patients with T2D, those with known CV disease and those at high risk who are receiving metformin have lower risks of death, myocardial infarction, and stroke if they are treated with GLP-1RAs, and those treated with SGLT2is have reduced risks of hospital admission for heart failure, CV mortality, and all-cause mortality.
Source: The American Journal of Cardiology - December 14, 2022 Category: Cardiology Authors: Lloyd W. Klein Source Type: research
Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions
This article reviews current pharmacotherapeutic options for prevention of stroke in NVAF, paying special attention to their use in particular clinical settings (e.g.: cardioversion, catheter ablation). We also aim to review new drug candidates that have entered clinical studies in this indication.EXPERT OPINION: Oral anticoagulant therapy (OAT) remains the mainstay for ischemic stroke prophylaxis in NVAF in patients at risk. Several oral (asundexian, milvexian) and parenteral (abelacimab, osocimab, xisomab, IONIS-FXIRX, fesomersen) factor XIa inhibitors are under development. These new compounds appear to be associated wi...
Source: Expert Opinion on Pharmacotherapy - November 18, 2022 Category: Drugs & Pharmacology Authors: Antonio G ómez-Outes M Luisa Su árez-Gea Alejandro-Isidoro P érez-Cabeza Jose Manuel Garc ía-Pinilla Source Type: research
Neuropharmacological efficacy of metformin for stroke in rodents: A meta-analysis of preclinical trials
Conclusion: Overall, metformin treatment improves severe outcomes triggered by stroke. Despite the limitations intrinsic to animal studies, this systematic review may provide a vital reference for future high-quality preclinical trials and clinical use.
Source: Frontiers in Pharmacology - November 3, 2022 Category: Drugs & Pharmacology Source Type: research
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study
CONCLUSION: As first-line agents, SGLT2 inhibitors and GLP1 receptor agonists would improve type 2 diabetes outcomes, but their costs would need to fall by at least 70% to be cost-effective.PRIMARY FUNDING SOURCE: American Diabetes Association.PMID:36191315 | DOI:10.7326/M21-2941
Source: Annals of Internal Medicine - October 3, 2022 Category: Internal Medicine Authors: Jin G Choi Aaron N Winn M Reza Skandari Melissa I Franco Erin M Staab Jason Alexander Wen Wan Mengqi Zhu Elbert S Huang Louis Philipson Neda Laiteerapong Source Type: research
